Stryker Corporation 2003 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Stryker Corporation (Stryker)
Reporting Period: Fiscal year ended December 31, 2003
Industry: Medical Devices and Orthopaedics
Overview: Stryker is a global leader in orthopaedic products and medical equipment. Operations are segmented into Orthopaedic Implants (joint replacements, trauma, spine, OP-1) and MedSurg Equipment (powered instruments, endoscopy, patient handling). The company also provides outpatient physical therapy services in the U.S. through Physiotherapy Associates.
Key Financial Metrics (2003)
| Metric | 2003 (in millions) | 2002 (in millions) | Change |
|---|---|---|---|
| Net Sales | $3,625.3 | $3,011.6 | +20.4% |
| Gross Profit | $2,312.9 | $1,900.4 | +21.7% |
| Gross Margin | 63.8% | 63.1% | +70 bps |
| Net Earnings | $453.5 | $345.6 | +31.2% |
| Diluted EPS | $2.23 | $1.70 | +31.2% |
| Operating Cash Flow | $648.5 | $516.2 | +25.6% |
| Total Assets | $3,159.1 | $2,815.5 | +12.2% |
| Long-Term Debt | $26.1 | $501.7 | -94.8% |
| Working Capital | $547.1 | $443.8 | +23.3% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% driven by a 23% rise in Orthopaedic Implants and 18% in MedSurg Equipment. Growth was fueled by volume/mix (12%), price (2%), foreign currency (5%), and acquisitions (1%).
- Debt Reduction: Long-term debt plummeted from $501.7 million to $26.1 million as the company aggressively paid down borrowings using strong operating cash flow.
- Profitability: Net earnings rose 31% to $453.5 million. The effective tax rate decreased to 30.5% (from 31.8%) due to increased manufacturing in lower-tax jurisdictions (Ireland, Puerto Rico).
- Restructuring: Unlike 2002, which included $17.2 million in restructuring charges (closing the Rutherford, NJ facility), 2003 had no such charges. However, a $6.5 million trademark impairment charge was recorded in Q4 2003.
- Foreign Currency: A favorable currency impact of $145.9 million boosted international sales, which grew 24% year-over-year.
Guidance, Outlook, and Risks
- 2004 Outlook: Management expects diluted net earnings per share to approximate $2.68. Net sales growth is projected at approximately 16%, driven by Orthopaedic and MedSurg shipments and favorable currency rates.
- Capital Allocation: The company anticipates investing in business acquisitions, new product launches, and facility expansions (specifically in the MedSurg segment).
- Legal Contingency: In December 2003, Stryker and its subsidiary Physiotherapy Associates received a subpoena from the U.S. Attorney's Office in Boston regarding billing and coding practices. The company is cooperating fully; potential financial impact is currently undetermined.
- Market Risks: Key risks include regulatory actions affecting pricing/reimbursement, product liability claims, foreign exchange fluctuations, and competition in orthopaedic and surgical markets.
Investor Verification Checklist
- Debt Status: Verify the sustainability of the low debt position ($26.1M) and the availability of the $802.1M credit facility for future acquisitions.
- Legal Exposure: Monitor the outcome of the Department of Justice investigation into Physiotherapy Associates' billing practices.
- 2004 Guidance: Track Q1 2004 results to validate the 16% sales growth and $2.68 EPS guidance, particularly regarding foreign currency impacts.
- Product Pipeline: Assess the commercial success of new 2003 launches (e.g., Trident Ceramic Acetabular System, CORE platform instruments) and the OP-1 Putty clinical trial progress.
- Margin Trends: Confirm if the 63.8% gross margin is sustainable given increased R&D spending (5.0% of sales) and SG&A costs (39.1% of sales).